Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: May 31, 2022 Report Code: GDGMDHC22193IDB-ST

Select Item

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Its signs and symptoms include sleep disturbances, including insomnia or sleeping too much, appetite changes, anxiety, agitation, or restlessness, and physical problems like back pain or headaches. Depression can be treated via antidepressants, mood stabilizers, or antipsychotics.

The Depression pipeline market research report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Key Targets in the Depression Pipeline Products Market

The key targets in the Depression pipeline products market are 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, Sodium Dependent Noradrenaline Transporter, Glutamate Ionotropic Receptor AMPA Type Subunit, Sodium Dependent Dopamine Transporter, 5-Hydroxytryptamine Receptor 7, D3 Dopamine Receptor, and others.

Depression Pipeline Products Analysis Market by Targets

Depression Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Depression Pipeline Products Market

The key mechanisms of action in the Depression pipeline products market are 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Sodium Dependent Serotonin Transporter Inhibitor, D2 Dopamine Receptor Antagonist, Sodium Dependent Noradrenaline Transporter Inhibitor, D2 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Sodium Dependent Dopamine Transporter Inhibitor, and others.

Depression Pipeline Products Market Analysis by Mechanisms of Action

Depression Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Depression Pipeline Products Market

The key routes of administration in the Depression pipeline products market are oral, intravenous, sublingual, subcutaneous, nasal, intramuscular, buccal, inhalational, parenteral, and transdermal.

Depression Pipeline Products Market Analysis by Routes of Administration

Depression Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Depression Pipeline Products Market

The key molecule types in the Depression pipeline products market are small molecule, biologic, peptide, synthetic peptide, recombinant protein, antisense RNAi oligonucleotide, cell therapy, and protein.

Depression Pipeline Products Market Analysis by Molecule Types

Depression Pipeline Products Market Analysis by Molecule Types

For more molecule type insights, download a free report sample

Major Companies in the Depression Pipeline Products Market

Some of the major companies in the Depression pipeline products market are Johnson & Johnson, Luye Pharma Group Ltd, Shenox Pharmaceuticals LLC, MD Healthcare Inc, Atai Life Sciences NV, H. Lundbeck AS, Intra-Cellular Therapies Inc, Korea Pharma Co Ltd, Neurocrine Biosciences Inc, and Otsuka Pharmaceutical Co Ltd.

Depression Pipeline Products Market Analysis by Companies

Depression Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Depression Pipeline Products Market Report Overview

Key Targets 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, Sodium Dependent Noradrenaline Transporter, Glutamate Ionotropic Receptor AMPA Type Subunit, Sodium Dependent Dopamine Transporter, 5-Hydroxytryptamine Receptor 7, D3 Dopamine Receptor, and Others
Key Mechanisms of Action 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Sodium Dependent Serotonin Transporter Inhibitor, D2 Dopamine Receptor Antagonist, Sodium Dependent Noradrenaline Transporter Inhibitor, D2 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Sodium Dependent Dopamine Transporter Inhibitor, and Others
Key Routes of Administration Oral, Intravenous, Sublingual, Subcutaneous, Nasal, Intramuscular, Buccal, Inhalational, Parenteral, and Transdermal
Key Molecule Type Small Molecule, Biologic, Peptide, Synthetic Peptide, Recombinant Protein, Antisense RNAi Oligonucleotide, Cell Therapy, and Protein
Major Companies Johnson & Johnson, Luye Pharma Group Ltd, Shenox Pharmaceuticals LLC, MD Healthcare Inc, Atai Life Sciences NV, H. Lundbeck AS, Intra-Cellular Therapies Inc, Korea Pharma Co Ltd, Neurocrine Biosciences Inc, and Otsuka Pharmaceutical Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

4M Therapeutics Inc
Actinogen Medical Ltd
Adamed Pharma SA
Adare Pharma Solutions
Addex Therapeutics Ltd
Aision Biotechnologies Inc
Alar Pharmaceuticals Inc
Alexza Pharmaceuticals Inc
Alkermes Plc
Alto Neuroscience Inc
Alzamend Neuro Inc
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Ancora Bio Inc
Angelini Spa
Antheia Inc
Apex Labs Ltd
Appello Pharmaceuticals Inc
Atai Life Sciences NV
Athira Pharma Inc
AtoGen Co Ltd
Autobahn Therapeutics Inc
Avanir Pharmaceuticals Inc
Avicanna Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
Baergic Bio Inc
Beckley Psytech Ltd
Benuvia Therapeutics Inc
Better Life Pharmaceuticals Inc
Biomind Labs Inc
BioXcel Therapeutics Inc
Blue Oak Pharmaceuticals Inc
Boehringer Ingelheim International GmbH
Braxia Scientific Corp
Bright Minds Biosciences Inc
Brii Biosciences Ltd
Bristol-Myers Squibb Co
Calico Life Sciences LLC
Camino Pharma LLC
CAR-T (Shanghai) Biotechnology Co Ltd
Cellix Bio Pvt Ltd
Celon Pharma SA
Cerevel Therapeutics Holdings Inc
Ceruvia Lifesciences LLC
CGeneTech (Suzhou China) Co Ltd
Chase Therapeutics Corp
Chengdu Jinrui Foundation Biotechnology Co Ltd
Clexio Biosciences Ltd
Compass Pathways Plc
Core One Labs Inc
CSPC Pharmaceutical Group Ltd
CuroNZ Ltd
Cybin Inc
Delix Therapeutics Inc
Delpor Inc
Denovo Biopharma LLC
Diamond Therapeutics Inc
Digestome Therapeutics Inc
Douglas Pharmaceuticals Ltd
Dracen Pharmaceuticals Inc
Eleusis Ltd
Eli Lilly and Co
Eliem Therapeutics Inc
Entheogenix Biosciences Inc
ES Therapeutics LLC
Ethismos Research Inc
Evecxia Therapeutics Inc
Evotec SE
Field Trip Health Inc
FSD Pharma Inc
Gabather AB
Gate Neurosciences Inc
GB Sciences Inc
Genesen Co Ltd
GH Research PLC
Gilgamesh Pharmaceuticals Inc
GliaCure Inc
GNT Pharma Co Ltd
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
H. Lundbeck AS
Halucenex Life Sciences Inc
HEC Pharma Co Ltd
HMNC Holding GmbH
Hua Medicine Shanghai Ltd
Iltoo Pharma
ImmunoBiome Inc
Impel Pharmaceuticals Inc
Initiator Pharma AS
Inmune Bio Inc
Innovimmune Biotherapeutics Inc
Intas Pharmaceuticals Ltd
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
iX Biopharma Ltd
Jazz Pharmaceuticals Plc
Jiangsu Gibel Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Jina Pharmaceuticals Inc
Johnson & Johnson
Kissei Pharmaceutical Co Ltd
Klaria Pharma Holding AB
Korea Pharma Co Ltd
Kures Inc
Lactocore Inc
LB Pharmaceuticals Inc
Lead Discovery Center GmbH
Lennham Pharmaceuticals Inc
Ligand Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Lophora ApS
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
MapLight therapeutics Inc
Mapreg SAS
Marvel Biotechnology Inc
MD Healthcare Inc
Medlab Clinical Ltd
MElkin Pharmaceuticals
Mental-Heal Ltd
Merck & Co Inc
Metys Pharmaceuticals AG
miCure Therapeutics Ltd
Midatech Pharma Plc
Mind Medicine MindMed Inc
MindBio Therapeutics Pty Ltd
Mindset Pharma Inc
MyMD Pharmaceuticals, Inc
MYND Life Sciences Inc
Navitor Pharmaceuticals Inc
Neonc Technologies Inc
Neumora Therapeutics Inc
Neurai Life Sciences
Neurocentrx Pharma Ltd
Neurocrine Biosciences Inc
Neurocyte Therapeutics Inc
Neurolixis Inc
NeuroNascent Inc
NeuroPharm Inc
Nippon Chemiphar Co Ltd
Novartis AG
NRX Pharmaceuticals Inc
Nubiyota LLC
Omeros Corp
Otsuka Pharmaceutical Co Ltd
Overseas Pharmaceuticals Ltd
OWP Pharmaceuticals Inc
Palisade Bio, Inc
Pasithea Therapeutics Corp
Pfizer Inc
PharmaMax Corp
PharmaTher Holdings Ltd
Pharmnovo AB
PharmoRx Therapeutics Inc
Phytecs
PNB Vesper Life Science Pvt Ltd
Praxis Precision Medicines Inc
Primetime Life Sciences LLC
Protagenic Therapeutics Inc
Prous Institute for Biomedical Research SA
Psirenity Inc
Psy Therapeutics Inc
PsyBio Therapeutics Corp
PsyProtix Inc
Puretech Health Plc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Relmada Therapeutics Inc
Reset Pharmaceuticals Inc
Reven Holdings Inc
Reviva Pharmaceuticals Inc
Revive Therapeutics Ltd
Revixia Life Sciences Inc
Richter Gedeon Nyrt
Rugen Therapeutics R&D (Shanghai) Co Ltd
Sage Therapeutics Inc
Saniona AB
Sansero Life Sciences Inc
Seed Health Inc
Seelos Therapeutics, Inc.
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai SIMR Biotech Co Ltd
Shanghai Zhimeng Biopharma Inc
Shenox Pharmaceuticals LLC
Shenzhen Salubris Pharmaceuticals Co Ltd
Siragen Pharmaceuticals Inc
Sirtsei Pharmaceuticals Inc
SK Biopharmaceuticals Co Ltd
Small Pharma Inc
Sound Pharmaceuticals Inc
Spirify Pharma Inc
Sumitomo Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Synaptogenix Inc
SyneuRx International Corp
Taisho Pharmaceutical Holdings Co Ltd
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Terran Biosciences Inc
Therapeutic Solutions International Inc
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Vanda Pharmaceuticals Inc
Viridia Life Sciences
VistaGen Therapeutics Inc
Vivozon Inc
Wake Network Inc
Wesana Health
Whan In Pharm Co Ltd
Xenon Pharmaceuticals Inc
XWPharma Ltd
Yangtze River Pharmaceutical Group
Yantai YenePharma Co Ltd
YSOPIA Bioscience SA
Yungjin Pharm Co Ltd
Zelira Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Depression – Overview

Depression – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Depression – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Depression – Companies Involved in Therapeutics Development

Depression – Drug Profiles

Depression – Dormant Projects

Depression – Discontinued Products

Depression – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets in the Depression products market?

    The key targets in the Depression pipeline products market are 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Glutamate Ionotropic Receptor NMDA Type Subunit, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, Sodium Dependent Noradrenaline Transporter, Glutamate Ionotropic Receptor AMPA Type Subunit, Sodium Dependent Dopamine Transporter, 5-Hydroxytryptamine Receptor 7, D3 Dopamine Receptor, and others.

  • What are the key mechanisms of action in the Depression pipeline products market?

    The key mechanisms of action in the Depression pipeline products market are 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, Sodium Dependent Serotonin Transporter Inhibitor, D2 Dopamine Receptor Antagonist, Sodium Dependent Noradrenaline Transporter Inhibitor, D2 Dopamine Receptor Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Sodium Dependent Dopamine Transporter Inhibitor, and others.

  • What are the key routes of administration in the Depression pipeline products market?

    The key routes of administration in the Depression pipeline products market are oral, intravenous, sublingual, subcutaneous, nasal, intramuscular, buccal, inhalational, parenteral, and transdermal.

  • What are the key molecule types in the Depression pipeline products market?

    The key molecule types in the Depression pipeline products market are small molecule, biologic, peptide, synthetic peptide, recombinant protein, antisense RNAi oligonucleotide, cell therapy, and protein.

  • Which are the major companies in the Depression pipeline products market?

    Some of the major companies in the Depression pipeline products market are Johnson & Johnson, Luye Pharma Group Ltd, Shenox Pharmaceuticals LLC, MD Healthcare Inc, Atai Life Sciences NV, H. Lundbeck AS, Intra-Cellular Therapies Inc, Korea Pharma Co Ltd, Neurocrine Biosciences Inc, and Otsuka Pharmaceutical Co Ltd.

Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Depression Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more